866-997-4948(US-Canada Toll Free)

Glyset (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 40 Pages


GlobalDatas pharmaceuticals report, Glyset (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Glyset sales estimates for US, France, Germany, Spain and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Glyset including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Glyset including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Glyset in the US, France, Germany,Spain and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Glyset 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Phase III Clinical Trials Evaluating Glyset in Non-Insulin Diabetes Mellitus Patients (NIDDM) Patients after Dietry Treatment Only. 25
7.3.2 Glyset in Non-Insulin Diabetes Mellitus Patients (NIDDM) Patients Receiving Sulfonylureas. 26
7.3.3 Glyset in Non Insulin Diabetes Mellitus Patients (NIDDM) Patients Receiving Metformin 27
7.4 Approval History of Glyset 27
7.5 Factors Affecting Sales of Glyset 27
7.5.1 Safety Profile 27
7.5.2 No Weight Gain 28
7.5.3 Patent Expiry of Miglitol 28
7.6 Drug Evaluation 28
7.6.1 Drug Risk Benefit Score 28
7.6.2 Intensity of Competition 29
7.7 Sales Estimates 30
7.7.1 Target Patient Pool for Glyset 30
7.7.2 Dosing 30
7.7.3 Market Penetration 30
7.7.4 Annual Cost of Therapy 30
7.7.5 Sales Estimates of Glyset 31

8 Diabetes Market: Appendix 37
8.1 Market Definitions 37
8.2 List of Abberiviations 37
8.3 Research Methodology 37
8.3.1 Coverage 38
8.3.2 Secondary Research 38
8.3.3 Forecasting 38
8.3.4 Net Penetration of Drug 39
8.3.5 Net Annual Dosing 39
8.3.6 Annual Cost of Therapy 39
8.3.7 Primary Research 39
8.3.8 Expert Panels 39
8.4 Contact Us 40
8.5 Disclaimer 40
8.6 Sources 40

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: Results of Monotherapy study with Glyset 26
Table 10: Glyset Approval History 27
Table 11: Drug Risk Benefit Score 28
Table 12: Glyset, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 31
Table 13: Glyset, Type 2 Diabetes, The US, Sales Estimates ($m), 20022014 32
Table 14: Glyset, Type 2 Diabetes, France, Sales Estimates ($m), 20022012 33
Table 15: Glyset, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022012 34
Table 16: Glyset, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022013 35
Table 17: Glyset, Type 2 Diabetes, Japan, Sales Estimates ($m), 20062020 36

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Glyset, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 31
Figure 13: Glyset, Type 2 Diabetes , The US, Sales Estimates ($m), 20022014 32
Figure 14: Glyset, Type 2 Diabetes, France, Sales Estimates ($m), 20022012 33
Figure 15: Glyset, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022012 34
Figure 16: Glyset, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022013 35
Figure 17: Glyset, Type 2 Diabetes, Japan, Sales Estimates ($m), 20062020 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *